Fractyl Health, Inc. Common Stock (GUTS) - Total Assets
Based on the latest financial reports, Fractyl Health, Inc. Common Stock (GUTS) holds total assets worth $81.98 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Fractyl Health, Inc. Common Stock - Total Assets Trend (2019–2025)
This chart illustrates how Fractyl Health, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see Fractyl Health, Inc. Common Stock market cap and net worth for the company's overall valuation and market capitalisation.
Fractyl Health, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (September 2025)
Fractyl Health, Inc. Common Stock's total assets of $81.98 Million consist of 72.1% current assets and 27.9% non-current assets. Review GUTS current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 67.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Fractyl Health, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See GUTS live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fractyl Health, Inc. Common Stock's current assets represent 72.1% of total assets in 2025, a decrease from 75.9% in 2019.
- Cash Position: Cash and equivalents constituted 67.2% of total assets in 2025, up from 64.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Fractyl Health, Inc. Common Stock Competitors by Total Assets
Key competitors of Fractyl Health, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Fractyl Health, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.15 | 1.22 | 7.87 |
| Quick Ratio | 3.15 | 1.22 | 7.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $33.87 Million | $4.86 Million | $89.79 Million |
Fractyl Health, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Fractyl Health, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.06 |
| Latest Market Cap to Assets Ratio | 0.77 |
| Asset Growth Rate (YoY) | 12.3% |
| Total Assets | $121.40 Million |
| Market Capitalization | $94.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values Fractyl Health, Inc. Common Stock's assets below their book value (0.77x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Fractyl Health, Inc. Common Stock's assets grew by 12.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Fractyl Health, Inc. Common Stock (2019–2025)
The table below shows the annual total assets of Fractyl Health, Inc. Common Stock from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $121.40 Million | +12.33% |
| 2024-09-30 | $108.08 Million | +41.81% |
| 2023-09-30 | $76.21 Million | +25.03% |
| 2022-09-30 | $60.96 Million | -40.56% |
| 2021-09-30 | $102.55 Million | +195.02% |
| 2020-09-30 | $34.76 Million | +289.08% |
| 2019-09-30 | $8.93 Million | -- |
About Fractyl Health, Inc. Common Stock
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a nove… Read more